Switch to a High-Intensity Statin First, Then Add Ezetimibe if Needed
If cholesterol isn't controlled on pravastatin 40 mg, you should first switch to a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) to achieve ≥50% LDL-C reduction, and only add ezetimibe if you still don't reach goal on maximally tolerated high-intensity statin therapy. 1
The Algorithmic Approach
Step 1: Determine the Patient's ASCVD Risk Category
The 2026 ACC/AHA guidelines provide clear risk-stratified targets 1:
- High risk (≥10% 10-year ASCVD risk): Target LDL-C <70 mg/dL and non-HDL-C <100 mg/dL
- Intermediate risk (5-10%): Target LDL-C <100 mg/dL and non-HDL-C <130 mg/dL
- Borderline risk (3-5%): Target LDL-C <100 mg/dL and non-HDL-C <130 mg/dL
Step 2: Recognize That Pravastatin 40 mg is Moderate-Intensity
Pravastatin 40 mg achieves only 30-40% LDL-C reduction—this is moderate-intensity therapy. The guidelines explicitly state that high-risk patients require high-intensity statin therapy to achieve ≥50% LDL-C reduction 1.
Step 3: Switch to High-Intensity Statin
For high-risk patients, the guideline recommendation (Class 1, Level A) is to use high-intensity statin therapy first 1. This means:
- Atorvastatin 40-80 mg, OR
- Rosuvastatin 20-40 mg
This approach will deliver the ≥50% LDL-C reduction needed for high-risk patients.
Step 4: Add Ezetimibe Only After Maximizing Statin
Only after the patient is on maximally tolerated statin therapy should you consider adding ezetimibe (Class 2a, Level B-R recommendation) if LDL-C goals are still not achieved 1.
Why This Sequence Matters
Guideline Hierarchy is Clear
The 2026 ACC/AHA guidelines establish a treatment hierarchy 1:
- First: Optimize statin intensity (high-intensity for high-risk patients)
- Second: Add ezetimibe if goals not met on maximally tolerated statin
- Third: Consider PCSK9 inhibitors or bempedoic acid if still not at goal
The Evidence on Adding vs. Switching
While research shows that adding ezetimibe to pravastatin provides greater LDL-C reduction than doubling pravastatin (34-42% reduction with ezetimibe/pravastatin vs. 31% with pravastatin 40 mg alone) 2, 3, this comparison is misleading for your clinical question.
The real comparison should be:
- Switching to high-intensity statin: 45-55% LDL-C reduction
- Adding ezetimibe to pravastatin 40 mg: 34-42% LDL-C reduction 2
Switching to high-intensity statin delivers superior LDL-C lowering compared to adding ezetimibe to moderate-intensity statin.
FDA Label Data Supports This Approach
The Zetia FDA label shows that when ezetimibe is added to pravastatin 40 mg, LDL-C reduction is 42% 2. However, switching to atorvastatin 40 mg alone achieves 45% reduction, and atorvastatin 80 mg achieves 54% reduction 2. High-intensity statin monotherapy outperforms moderate-intensity statin plus ezetimibe.
Common Pitfalls to Avoid
Pitfall #1: Adding Ezetimibe Too Early
Many clinicians add ezetimibe before maximizing statin intensity. This violates guideline recommendations and may leave patients undertreated. The guidelines are explicit: ezetimibe is for patients on "maximally tolerated statin" 1.
Pitfall #2: Staying on Pravastatin
Pravastatin is the least potent statin. If a patient needs more LDL-C lowering, staying on pravastatin (even with ezetimibe) is suboptimal. The 2022 ACC Expert Consensus specifically notes drug interactions: "Avoid concomitant pravastatin >40 mg daily" with bempedoic acid 4, suggesting pravastatin has limited dose escalation potential.
Pitfall #3: Not Considering Statin Intolerance
If the patient is on pravastatin 40 mg due to statin intolerance (not just inadequate efficacy), then the algorithm changes:
- Try switching to a different high-intensity statin first (rosuvastatin may be better tolerated)
- If truly statin-intolerant, then adding ezetimibe to the maximally tolerated statin dose is appropriate 1
When Combination Therapy Makes Sense
Adding ezetimibe to ongoing statin is appropriate when:
- Patient is already on high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg)
- LDL-C goals still not achieved
- Patient cannot tolerate higher statin doses due to side effects 1
In these scenarios, adding ezetimibe provides an additional 15-20% LDL-C reduction 2, 5, 6.
The Real-World Consideration
Recent meta-analyses suggest that moderate-intensity statin plus ezetimibe may have better adherence and tolerability than high-intensity statin monotherapy 7, 8, 9. However, these studies don't override guideline recommendations, which prioritize maximizing statin intensity first for patients at high cardiovascular risk. The 2026 ACC/AHA guidelines are based on cardiovascular outcomes data showing mortality benefit with high-intensity statins 1.
For primary prevention in lower-risk patients, the calculus may differ, but for high-risk patients (which includes most patients not controlled on pravastatin 40 mg), high-intensity statin remains the evidence-based first step.